PMID- 27605069
OWN - NLM
STAT- MEDLINE
DCOM- 20170626
LR  - 20181113
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Print)
IS  - 1750-743X (Linking)
VI  - 8
IP  - 10
DP  - 2016 Oct
TI  - Combination strategies to enhance the potency of monocyte-derived dendritic 
      cell-based cancer vaccines.
PG  - 1205-18
LID - 10.2217/imt-2016-0071 [doi]
AB  - Dendritic cells (DCs) are potent inducers of adaptive immunity and their clinical 
      use in cancer vaccine formulations remains an area of active translational and 
      clinical investigation. Although cancer vaccines applied as monotherapies have 
      had a modest history of clinical success, there is great enthusiasm for novel 
      therapeutic strategies combining DC-based cancer vaccines with agents that 
      'normalize' immune function in the tumor microenvironment (TME). Broadly, these 
      combination vaccines are designed to antagonize/remove immunosuppressive networks 
      within the TME that serve to limit the antitumor action of vaccine-induced T 
      cells and/or to condition the TME to facilitate the recruitment and optimal 
      function and durability of vaccine-induced T cells. Such combination regimens are 
      expected to dramatically enhance the clinical potency of DC-based cancer vaccine 
      platforms.
FAU - Fecek, Ronald J
AU  - Fecek RJ
AD  - Department of Dermatology, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA 15213, USA.
FAU - Storkus, Walter J
AU  - Storkus WJ
AD  - Department of Dermatology, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA 15213, USA.
AD  - Department of Immunology, University of Pittsburgh School of Medicine, PA, USA.
AD  - Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.
AD  - Department of Bioengineering, University of Pittsburgh School of Medicine, PA, 
      USA.
AD  - University of Pittsburgh Cancer Institute, PA, USA.
LA  - eng
GR  - P50 CA121973/CA/NCI NIH HHS/United States
GR  - R01 CA140375/CA/NCI NIH HHS/United States
GR  - R01 CA169118/CA/NCI NIH HHS/United States
GR  - R01 CA204419/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Costimulatory and Inhibitory T-Cell Receptors)
RN  - 0 (Glucocorticoid-Induced TNFR-Related Protein)
RN  - 0 (TNFRSF18 protein, human)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Cancer Vaccines/*immunology
MH  - Combined Modality Therapy
MH  - Costimulatory and Inhibitory T-Cell Receptors/immunology
MH  - Dendritic Cells/immunology/*transplantation
MH  - Glucocorticoid-Induced TNFR-Related Protein/immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Lymphocyte Activation
MH  - Monocytes/immunology
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/*immunology
MH  - Tumor Microenvironment
PMC - PMC5619021
OTO - NOTNLM
OT  - cancer
OT  - combination immunotherapy
OT  - dendritic cell
OT  - immunoconditioning
OT  - immunoregulation
OT  - targeted therapy
OT  - vaccine
COIS- Financial & competing interests disclosure This work was supported by NIH R01 
      grant CA169118 (to WJ Storkus) and a Career Enhancement Program Award from the 
      University of Pittsburgh's Melanoma and Skin Cancer SPORE P50 CA121973 (to RJ 
      Fecek). The authors have no other relevant affiliations or financial involvement 
      with any organization or entity with a financial interest in or financial 
      conflict with the subject matter or materials discussed in the manuscript apart 
      from those disclosed. No writing assistance was utilized in the production of 
      this manuscript.
EDAT- 2016/09/09 06:00
MHDA- 2017/06/27 06:00
PMCR- 2017/10/01
CRDT- 2016/09/09 06:00
PHST- 2016/09/09 06:00 [entrez]
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2017/06/27 06:00 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
AID - 10.2217/imt-2016-0071 [doi]
PST - ppublish
SO  - Immunotherapy. 2016 Oct;8(10):1205-18. doi: 10.2217/imt-2016-0071.